Article

Activation of AMPK inhibits inflammation in MRL/lpr mouse mesangial cells.

Virginia College of Osteopathic Medicine, Blacksburg, VA 24060, USA.
Clinical & Experimental Immunology (Impact Factor: 3.41). 07/2009; 156(3):542-51. DOI: 10.1111/j.1365-2249.2009.03924.x
Source: PubMed

ABSTRACT Recent reports show that 5-amino-4-imidazole carboxamide riboside (AICAR), a pharmacological activator of AMP-activated protein kinase (AMPK), inhibits the lipopolysaccharide (LPS)-induced production of proinflammatory cytokines. MRL/MPJ-Fas(lpr) (MRL/lpr) mice show an intrinsic decreased threshold for the production of inflammatory mediators when stimulated. In our current studies, we sought to determine if AMPK activation would inhibit inflammatory mediator production in stimulated kidney mesangial cells. Cultured mesangial cells from MRL/lpr mice were treated with AICAR and stimulated with LPS/interferon (IFN)-gamma. AICAR decreased dose-dependently inducible nitric oxide synthase (iNOS), cyclooxygenase-2 and interleukin-6 production in LPS/IFN-gamma-stimulated mesangial cells. Mechanistically, AICAR inhibited the LPS/IFN-gamma-stimulated PI3K/Akt signalling inflammatory cascade but did not affect LPS/IFN-gamma-mediated inhibitory kappa B phosphorylation or nuclear factor (NF)-kappaB (p65) nuclear translocation. Treatment with the adenosine kinase inhibitor 5'-iodotubercidin blocked the ability of AICAR to activate AMPK and prevented AICAR from inhibiting the LPS/IFN-gamma-stimulated PI3K/Akt pathway and attenuating iNOS expression. Taken together, these observations suggest that AICAR inhibits LPS/IFN-gamma-induced Akt phosphorylation through AMPK activation and may serve as a potential therapeutic target in inflammatory diseases.

0 Bookmarks
 · 
166 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Kidney transplantation represents the best treatment of end-stage renal disease. In addition to the degree of human leukocyte antigen matching, long-term graft survival is influenced by the quality of the graft before its transplantation. Quality criteria include the level of ischemic damage caused by the transplantation per se. Renal ischemic preconditioning (IP) consists of different approaches to prevent ischemia/reperfusion (I/R) damage induced by the interruption and recovery of renal circulation, as observed during transplantation. Distinct animal models show promising results regarding the efficiency of PCI to preserve kidney structure and function in I/R conditions. Characterizing the cellular cascades involved in I/R led to the identification of putative targets of renal IP, including the adenosine monophosphate-activated protein kinase (AMPK). AMPK is a ubiquitous energy sensor, which has been implicated in the maintenance of epithelial cell polarization under energy deprivation. Among others, the anti-diabetic drug, metformin, is a potent activator of AMPK. Here, we summarize the in vitro and in vivo data about the role of AMPK in renal IP. Defining the pharmacological conditions of IP would help to improve the quality of the renal graft before its transplantation, thereby increasing its long-term survival.
    Néphrologie & Thérapeutique 12/2013; · 0.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: ABSTRACT The aims of the present study were to examine the effect of AMPK activation on pulmonary arterial smooth muscle cells (PASMCs) proliferation and to address its potential mechanisms. ET-1 dose and time-dependently induced PASMCs proliferation, and this effect was suppressed by a selective AMPK activator metformin. The results of the study further indicated that the proliferation of PASMCs stimulated by ET-1 was associated with the increase of Skp2 and decrease of p27, and metformin reversed ET-1-induced Skp2 elevation and raised p27 protein level. Our study suggests that activation of AMPK suppresses PASMCs proliferation and has potential value in negatively modulating pulmonary vascular remodeling and therefore could prevent or treat the development of pulmonary arterial hypertension (PAH).
    Experimental Lung Research 06/2014; 40(5):251-8. · 1.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The rat kidney ablation and infarction (A/I) model of subtotal or 5/6(th) nephrectomy is the most commonly studied model of non-diabetic chronic kidney disease (CKD). The A/I kidney at one-week exhibits reductions in kidney function as determined by glomerular filtration rate (GFR), and diminished metabolic efficiency as determined by oxygen consumption per sodium transport (QO2/TNa). As renoprotective adenosine monophosphate-activated protein kinase (AMPK) activity is affected by metabolic changes and cellular stress, we evaluated AMPK activity in this model system. We show that these early pathophysiologic changes are accompanied by a paradoxical decrease in AMPK activity. Over time these kidney parameters progressively worsen with extensive kidney structural, functional, metabolic and fibrotic changes observed at four weeks post A/I. We show that induction of AMPK activity with either metformin or AICAR increases AMPK activity in this model, and also corrects kidney metabolic inefficiency, improves kidney function and ameliorates kidney fibrosis and structural alterations. We conclude that AMPK activity is reduced in the subtotal nephrectomy model of non-diabetic CKD; that altered regulation of AMPK is coincident with the progression of disease parameters; and that restoration of AMPK activity can suppress the progressive loss of function characteristic of this model. We propose that induction of AMPK activity may prove an effective therapeutic target for the treatment of non-diabetic CKD.
    AJP Renal Physiology 07/2013; · 4.42 Impact Factor

Full-text (2 Sources)

View
31 Downloads
Available from
Jun 6, 2014